While the reduction in price target from $310 to $305 by Canaccord Genuity could be seen as a slight negative sentiment, the maintenance of a Buy rating by analyst Sumant Kulkarni suggests a continued positive outlook on Biogen's stock in the short term. The impact is likely neutral as the decrease in target price is minimal and the Buy rating remains unchanged, indicating confidence in the company's future performance.